Galectin Therapeutics GALT 深 滬
等待開盤 12-24 09:30:00 美东时间
3.99
-0.040
-0.99%
華盛通- 最 高4.13
- 今 開4.00
- 成交量 105.24万股
- 最 低 3.53
- 昨 收 4.03
- 總市值 2.56亿
- 52周最高 7.13
- 市盈率 靜 --
- 換手率 1.64%
- 52周最低 1.07
- 委 比 15.06%
- 總股本 6406.03万
- 歷史最高 19.11
- 量 比 0.73
- 振 幅 14.89%
- 歷史最低 0.49
- 每 手 1
- 風險率 1.75%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Galectin Advances Belapectin Program, Secures New Insider Financing
Galectin Therapeutics ( ($GALT) ) has issued an update. On December 19, 2025, G...
12-19 21:14
美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
12-18 10:54
HC Wainwright & Co. Maintains Buy on Galectin Therapeutics, Raises Price Target to $11
HC Wainwright & Co. analyst Matthew Keller maintains Galectin Therapeutics (NASDAQ:GALT) with a Buy and raises the price target from $6 to $11.
12-17 20:44
PureTech Health Announces Initial Topline Results From Phase 1b Clinical Trial Evaluating LYT-200, Anti-Galectin-9 Monoclonal Antibody, In Patients With r/r AML And High-Risk MDS
LYT-200 demonstrated favorable tolerability and strong efficacy in a heavily pretreated population, both in combination with standard of care and as a monotherapy, supporting advancement toward a potentially
12-06 02:02
Galectin Therapeutics Reveals Promising NAVIGATE Trial Results
Galectin Therapeutics ( ($GALT) ) just unveiled an announcement. On December 3,...
12-04 01:28
Galectin Therapeutics GAAP EPS of -$0.13
Galectin Therapeutics press release (GALT): Q3 GAAP EPS of -$0.13. More on Galectin Therapeutics Galectin: With Time Ticking, A Partner Is Needed To Revitalize MASH Program Seeking Alpha’s Quant Ratin...
11-14 21:10
Galectin Therapeutics Presented NAVIGATE Trial Results at the American Association for the Study of Liver Diseases (AASLD) 2025 Annual Meeting
The Phase 2 NAVIGATE trial demonstrates that belapectin 2 mg/kg consistently reduces liver stiffness, new variceal development, and improves biomarkers in patients with compensated MASH cirrhosis and portal hypertension, with significant antifibrotic and disease-modifying potential.
11-10 13:00
PureTech Health To Share New Data From Ongoing Phase 1b Clinical Trial Evaluating LYT-200, Anti-Galectin-9 Monoclonal Antibody, In r/rAML At ASH 2025
LYT-200 continues to demonstrate strong evidence of clinical activity, survival benefit and a highly favorable safety profile in heavily pretreated relapsed/refractory AML patients, both as a monotherapy and in
11-03 22:18
Galectin Therapeutics to Present at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2025
<p><p align="justify">**Galectin Therapeutics Inc. (NASDAQ: GALT)** announced its participation in the **AASLD Liver Meeting 2025** held in **Washington, DC, USA, November 7-11, 2025**. The company will present **two sessions** related to the **NAVIGATE trial assessing belapectin** for treating **MASH cirrhosis**:</p><p align="justify">- **Oral Presentation:** Highlighting belapectin's ability to reduce liver stiffness and prevent varices over 18...
10-07 12:00
Stitch Fix Posts Q4 Results, Joins Transocean, MBX Biosciences And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Thursday. Shares of Stitch Fix, Inc. (NASDAQ: SFIX) dipped 7.6% to $5.21 in pre-market trading following the release of fourth-quarter results.
09-25 20:24
